StockData
Longeveron Inc. logo

Longeveron Inc. (LGVN) stock

LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.92−0.19 (-9.00%)

Close on Nov 18, 2026Market cap $61.21MP/E –Yield –

Longeveron cash

Cash and short-term investments held at the end of each period.

Longeveron's cash was $10.08M at Jun 30, 2026. For fiscal 2025 it was $4.66M, down 75.8% from the year before. The highest annual figure on record is $19.66M in fiscal 2022.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.66M-75.8%
FY2024Dec 31, 2024$19.23M+258.7%
FY2023Dec 31, 2023$5.36M-72.7%
FY2022Dec 31, 2022$19.66M+97.3%
FY2021Dec 31, 2021$9.96M+1120.9%
FY2020Dec 31, 2020$816.00K-56.3%
FY2019Dec 31, 2019$1.87M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$10.08M-2.5%
Q1 FY2026Mar 31, 2026$15.76M+10.0%
Q4 FY2025Dec 31, 2025$4.66M-75.8%
Q3 FY2025Sep 30, 2025$9.24M-59.4%
Q2 FY2025Jun 30, 2025$10.33M-16.5%
Q1 FY2025Mar 31, 2025$14.33M+525.4%
Q4 FY2024Dec 31, 2024$19.23M+258.7%
Q3 FY2024Sep 30, 2024$22.78M+479.2%
Q2 FY2024Jun 30, 2024$12.38M+350.5%
Q1 FY2024Mar 31, 2024$2.29M-0.4%
Q4 FY2023Dec 31, 2023$5.36M-72.7%
Q3 FY2023Sep 30, 2023$3.93M-80.6%
Q2 FY2023Jun 30, 2023$2.75M-87.6%
Q1 FY2023Mar 31, 2023$2.30M-76.9%
Q4 FY2022Dec 31, 2022$19.66M+3.6%
Q2 FY2022Jun 30, 2022$20.22M-5.4%
Q1 FY2022Mar 31, 2022$22.13M-9.5%
Q4 FY2021Dec 31, 2021$9.96M+1120.9%
Q3 FY2021Sep 30, 2021$18.97M+1260.8%
Q2 FY2021Jun 30, 2021$21.39M+1189.2%
Q1 FY2021Mar 31, 2021$24.46M+887.1%
Q4 FY2020Dec 31, 2020$816.00K-56.3%
Q3 FY2020Sep 30, 2020$1.39M–
Q2 FY2020Jun 30, 2020$1.66M–
Q1 FY2020Mar 31, 2020$2.48M–
Q4 FY2019Dec 31, 2019$1.87M–

More Longeveron figures

See a number that looks wrong?